KYOCERA Medical Technologies, Inc.

ReBOSSIS®

The Only Biosynthetic Scaffold with Electrospun Microfiber Construction



ReBOSSIS®

THE ONLY BIOSYNTHETIC SCAFFOLD WITH ELECTROSPUN MICROFIBER CONSTRUCTION

- Proven to support cell activation, retention, and proliferation[1]
- Superior handling characteristics[2]
- Optimal fit and fill:
  - ReBOSSIS® offers up to 54% compression recovery[3]
  - Maintains integrity during and after placement

ABOUT ReBOSSIS®

ReBOSSIS is the only biosynthetic bone scaffold with electrospun microfiber construction. Composed of β-TCP, $CaCO_3$, silicon, and PLGA, the special formula contains 0.5% to 1% silicon by weight, which is comparable to the level found in natural bone.

The interconnected network of microporous fibers in ReBOSSIS is created by a unique and proprietary electrospinning process that produces an absorbent, biodegradable scaffold. ReBOSSIS is known for its moldable properties, as well as for its ability to retain bioactive fluids, which enhances its osteoinductive potential.









[1]Based on results of 2017 tests carried out at the Cleveland Clinic Lerner Research Institute | [2]Based on user survey responses | [3]Test results available upon request

DEMONSTRATED EFFECTIVENESS

In a recent test by Dr. George Muschler, MD at the Cleveland Clinic Lerner Research Institute, osteoprogenitor cells were separated from bone marrow and were applied to ReBOSSIS fibers. The resulting cultures were carefully scrutinized at various stages. Staining and microscopic analysis showed robust cell growth migration and proliferation of cells on the fiber scaffold, indicating that cell colonies were growing and expanding on the microfibers—an early sign of bone formation. This test demonstrated that ReBOSSIS functions as an effective bone graft that supports cell vitality and adherence.



De novo ReBOSSIS fibers prior to infiltration & attachment





ECM formation - 3 days



Cell colonization & attachment - 11 days

PRODUCTS

Product Number	Pre-Hydration Volume	Fluid Absorption
ORB-0304C	10mL	3.5mL
ORB-0307C	18mL	6mL
ORB-0310C	25mL	8mL
ORB-0320C	50mL	16mL



*The volume of ReBOSSIS® decreases if the product is hydrated (optional). Change in volume depends on specimen and hydration material.

KYOCERA

ReBOSSIS®

Composed of β-TCP, $CaCO_3$, silicon, and PLGA, the special formula contains 0.5% to 1% silicon by weight, which is comparable to the level found in natural bone.

INDICATIONS FOR USE

ReBOSSIS is intended for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. ReBOSSIS is indicated to be packed gently into bony voids or gaps of the skeletal system (extremities, pelvis, and posterolateral spine). In the extremities and pelvis ReBOSSIS may be used without hydration or hydrated with blood. In the posterolateral spine ReBOSSIS is to be used hydrated with bone marrow aspirate and mixed with autograft bone. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process.

KYOCERA Medical Technologies, Inc.
1200 California Street, Ste 210, Redlands, CA 92374
Tel: (909) 557-2360 Fax: (909) 839-6269
www.kyocera-medical.com